Efficacy and Safety of Umifenovir for Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-analysis

Overview

Journal J Med Virol

Specialty Microbiology

Date 2020 Jul 4

PMID 32617989

Citations 50

Authors

Dong Huang

He Yu

Ting Wang

Huan Yang

Rong Yao

Zongan Liang

Affiliations

Soon will be listed here.

Abstract

We conducted this systemic review and meta-analysis in an attempt to evaluate the efficacy and safety of umifenovir in coronavirus disease 2019 (COVID-19). We searched PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure, and medRxiv database. We included both retrospective and prospective studies. The mean difference (MD) and risk ratio (RR) with 95% confidence intervals (CI) were applied to assess the effectiveness of umifenovir for COVID-19. A total of 12 studies with 1052 patients were included in our final studies. Compared with control group, umifenovir was associated with higher negative rate of PCR on day 14 (RR:1.27; 95% CI: 1.04 to 1.55). However, umifenovir is not related to nucleus acid negative conversion time (MD: 0.09; 95% CI: -1.48 to 1.65), negative rate on day 7 (RR:1.09; 95% CI: 0.91 to 1.31), incidence of composite endpoint (RR:1.20; 95% CI: 0.61 to 2.37), rate of fever alleviation on day 7 (RR:1.00; 95% CI: 0.91 to 1.10), rate of cough alleviation on day 7 (RR:1.00; 95% CI: 0.85 to 1.18), or hospital length of stay (MD: 1.34; 95% CI: -2.08 to 4.76). Additionally, umifenovir was safe in COVID-19 patients (RR for incidence of adverse events: 1.29; 95% CI: 0.57 to 2.92). The results of sensitivity analysis and subgroup analysis were similar to pooled results. There is no evidence to support the use of umifenovir for improving patient-important outcomes in patients with COVID-19.

Citing Articles

Acute Schizophrenia-like Psychotic Disorder Against the Background of COVID-19.

Bravve L, Kaydan M, Kostyuk G Medicina (Kaunas). 2025; 61(2).

PMID: 40005415 PMC: 11857278. DOI: 10.3390/medicina61020298.

Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses.

Luong Q, Hoang P, Ho P, Ayun R, Lee T, Lee S Int J Mol Sci. 2025; 26(4).

PMID: 40003946 PMC: 11855616. DOI: 10.3390/ijms26041481.

Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.

Mia M, Howlader M, Akter F, Hossain M Clin Pathol. 2024; 17:2632010X241263054.

PMID: 39070952 PMC: 11282570. DOI: 10.1177/2632010X241263054.

COVID-19 and coronary artery disease; A systematic review and meta-analysis.

Hajikhani B, Safavi M, Bostanshirin N, Sameni F, Ghazi M, Yazdani S New Microbes New Infect. 2023; 53:101151.

PMID: 37275509 PMC: 10205132. DOI: 10.1016/j.nmni.2023.101151.

Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.

Zielinska A, Eder P, Karczewski J, Szalata M, Hryhorowicz S, Wielgus K Front Immunol. 2023; 14:1147991.

PMID: 37033914 PMC: 10073701. DOI: 10.3389/fimmu.2023.1147991.

References

Tran B, Vu G, Latkin C, Pham H, Phan H, Le H . Characterize health and economic vulnerabilities of workers to control the emergence of COVID-19 in an industrial zone in Vietnam. Saf Sci. 2020; 129:104811. PMC: 7214303. DOI: 10.1016/j.ssci.2020.104811. View

Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H . Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect. 2020; 81(1):e1-e5. PMC: 7156152. DOI: 10.1016/j.jinf.2020.03.002. View

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-1578. PMC: 7190303. DOI: 10.1016/S0140-6736(20)31022-9. View

Gao H, Lu H, Cao B, Du B, Shang H, Gan J . Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013; 368(24):2277-85. DOI: 10.1056/NEJMoa1305584. View

Xu P, Huang J, Fan Z, Huang W, Qi M, Lin X . Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect. 2020; 22(4-5):200-205. PMC: 7238991. DOI: 10.1016/j.micinf.2020.05.012. View

Ho R, Thiaghu C, Ong H, Lu Y, Ho C, Tam W . A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2015; 15(2):124-38. DOI: 10.1016/j.autrev.2015.10.003. View

Wang X, Cao R, Zhang H, Liu J, Xu M, Hu H . The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020; 6:28. PMC: 7195821. DOI: 10.1038/s41421-020-0169-8. View

Sheahan T, Sims A, Leist S, Schafer A, Won J, Brown A . Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020; 11(1):222. PMC: 6954302. DOI: 10.1038/s41467-019-13940-6. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

10.

McKee D, Sternberg A, Stange U, Laufer S, Naujokat C . Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020; 157:104859. PMC: 7189851. DOI: 10.1016/j.phrs.2020.104859. View

11.

Wang C, Pan R, Wan X, Tan Y, Xu L, McIntyre R . A longitudinal study on the mental health of general population during the COVID-19 epidemic in China. Brain Behav Immun. 2020; 87:40-48. PMC: 7153528. DOI: 10.1016/j.bbi.2020.04.028. View

12.

Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q . Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020; 26(7):917-921. PMC: 7182750. DOI: 10.1016/j.cmi.2020.04.026. View

13.

Lan X, Shao C, Zeng X, Wu Z, Xu Y . Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study. Int J Clin Pharmacol Ther. 2021; 59(5):378-385. DOI: 10.5414/CP203861. View

14.

Ng A, Tam W, Zhang M, Ho C, Husain S, McIntyre R . IL-1β, IL-6, TNF- α and CRP in Elderly Patients with Depression or Alzheimer's disease: Systematic Review and Meta-Analysis. Sci Rep. 2018; 8(1):12050. PMC: 6089986. DOI: 10.1038/s41598-018-30487-6. View

15.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

16.

Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z . Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2020; 93(1):481-490. PMC: 7361300. DOI: 10.1002/jmv.26256. View

17.

Peng H, Gao P, Xu Q, Liu M, Peng J, Wang Y . Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes. J Clin Virol. 2020; 128:104425. PMC: 7204737. DOI: 10.1016/j.jcv.2020.104425. View

18.

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W . Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369:m1849. PMC: 7221473. DOI: 10.1136/bmj.m1849. View

19.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

20.

Blaising J, Polyak S, Pecheur E . Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014; 107:84-94. PMC: 7113885. DOI: 10.1016/j.antiviral.2014.04.006. View